Importantly, the highest doses (3 μM olaparib + 1 μM AZD6738) only caused moderate (39%) growth inhibition in WT cells (Fig. 1aii), suggesting a therapeutic window in ATM-deficient cancers. This evidence concerns the gene ATM and cancer.